Discovery of Candidate DNA Methylation Cancer Driver Genes.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
09 2021
Historique:
received: 17 09 2020
revised: 25 02 2021
accepted: 15 04 2021
pubmed: 12 5 2021
medline: 1 4 2022
entrez: 11 5 2021
Statut: ppublish

Résumé

Epigenetic alterations, such as promoter hypermethylation, may drive cancer through tumor suppressor gene inactivation. However, we have limited ability to differentiate driver DNA methylation (DNAme) changes from passenger events. We developed DNAme driver inference-MethSig-accounting for the varying stochastic hypermethylation rate across the genome and between samples. We applied MethSig to bisulfite sequencing data of chronic lymphocytic leukemia (CLL), multiple myeloma, ductal carcinoma

Identifiants

pubmed: 33972312
pii: 2159-8290.CD-20-1334
doi: 10.1158/2159-8290.CD-20-1334
pmc: PMC8419066
mid: NIHMS1700591
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2266-2281

Subventions

Organisme : NCI NIH HHS
ID : DP2 CA239065
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229902
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Cancer Res. 2009 Sep 1;69(17):6782-9
pubmed: 19706769
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Genome Biol. 2012 Oct 03;13(10):R92
pubmed: 23034176
Brief Bioinform. 2016 Sep;17(5):796-807
pubmed: 26515532
Nature. 2014 Sep 4;513(7516):115-9
pubmed: 25043040
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
Oncogene. 2020 Feb;39(6):1273-1289
pubmed: 31636387
J Immunol. 2013 Jul 15;191(2):892-901
pubmed: 23776175
Cancer Cell. 2014 Dec 8;26(6):813-825
pubmed: 25490447
Biometrika. 1968 Mar;55(1):1-17
pubmed: 5661047
Lancet. 2010 Oct 2;376(9747):1164-74
pubmed: 20888994
Nat Rev Genet. 2005 Aug;6(8):597-610
pubmed: 16136652
Blood. 2016 Jan 14;127(2):208-15
pubmed: 26486789
Leukemia. 2017 Sep;31(9):1882-1893
pubmed: 28017968
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):
pubmed: 27194046
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Cancer Res. 2019 Jan 15;79(2):360-371
pubmed: 30498085
Oncotarget. 2016 Sep 27;7(39):63456-63465
pubmed: 27566572
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9
pubmed: 17613547
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Psychol Bull. 1951 May;48(3):156-8
pubmed: 14834286
Nat Genet. 2012 Nov;44(11):1207-14
pubmed: 23064413
Nat Biotechnol. 2014 Dec;32(12):1262-7
pubmed: 25184501
Nat Commun. 2015 Apr 20;6:6921
pubmed: 25891015
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Genome Biol. 2012 Oct 03;13(10):R87
pubmed: 23034086
Sci Rep. 2019 Mar 20;9(1):4902
pubmed: 30894629
Cancer Res. 2015 Sep 15;75(18):3980-90
pubmed: 26249178
Genome Biol. 2018 Nov 6;19(1):187
pubmed: 30400938
Nat Genet. 2016 Mar;48(3):253-64
pubmed: 26780610
Endocrinology. 2012 Jul;153(7):2963-73
pubmed: 22562171
Cancers (Basel). 2019 Jul 09;11(7):
pubmed: 31323949
Nat Rev Clin Oncol. 2018 Jul;15(7):459-466
pubmed: 29666440
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Nat Rev Genet. 2017 Jul;18(7):441-451
pubmed: 28555657
Nat Med. 2018 Oct;24(10):1611-1624
pubmed: 30150718
Bioinformatics. 2011 Jun 1;27(11):1571-2
pubmed: 21493656
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Methods. 2017 Apr;14(4):407-410
pubmed: 28218898
Oncogene. 2010 Apr 8;29(14):2104-17
pubmed: 20154727
Nucleic Acids Res. 2019 Jul 2;47(W1):W171-W174
pubmed: 31106371
J Stat Softw. 2011 Mar;39(5):1-13
pubmed: 27065756
Science. 2019 Jun 28;364(6447):
pubmed: 31249028
Cell Death Dis. 2018 Jul 3;9(7):741
pubmed: 29970906

Auteurs

Heng Pan (H)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.

Loïc Renaud (L)

New York Genome Center, New York, New York.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.
Inserm, UMR-S 1172, Lille, France.

Ronan Chaligne (R)

New York Genome Center, New York, New York.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.

Johannes Bloehdorn (J)

Department of Internal Medicine III, Ulm University, Ulm, Germany.

Eugen Tausch (E)

Department of Internal Medicine III, Ulm University, Ulm, Germany.

Daniel Mertens (D)

German Cancer Research Center (DKFZ), Heidelberg, Germany.

Anna Maria Fink (AM)

German CLL Study Group, and Department I of Internal Medicine, and Center of Integrated Oncology ABCD, University of Cologne, Cologne, Germany.

Kirsten Fischer (K)

German CLL Study Group, and Department I of Internal Medicine, and Center of Integrated Oncology ABCD, University of Cologne, Cologne, Germany.

Chao Zhang (C)

Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.

Doron Betel (D)

Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.

Andreas Gnirke (A)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Marcin Imielinski (M)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.
New York Genome Center, New York, New York.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

Jérôme Moreaux (J)

IGH, CNRS, Univ Montpellier, France.
CHU Montpellier, Department of Biological Hematology, Montpellier, France.
UFR de Médecine, Univ Montpellier, Montpellier, France.
Institut Universitaire de France (IUF), France.

Michael Hallek (M)

German CLL Study Group, and Department I of Internal Medicine, and Center of Integrated Oncology ABCD, University of Cologne, Cologne, Germany.

Alexander Meissner (A)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Max Planck Institute for Molecular Genetics, Berlin, Germany.

Stephan Stilgenbauer (S)

Department of Internal Medicine III, Ulm University, Ulm, Germany.

Catherine J Wu (CJ)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Dana-Farber Cancer Institute, Boston, Massachusetts.

Olivier Elemento (O)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.

Dan A Landau (DA)

Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York. dlandau@nygenome.org.
New York Genome Center, New York, New York.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH